Evidence map›Paper›PMID 36428706›Full record

ReviewCancers2022

Targeting PTEN Regulation by Post Translational Modifications.

Ana González-García, Antonio Garrido, Ana C Carrera

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Postexercise downregulation ofTranslational cancer research · 2024
    Article
  18. Article
  19. Review
  20. PTEN: an emerging target in rheumatoid arthritis?Cell communication and signaling : CCS · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ana González-GarcíaDepartment of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid, Cantoblanco, E-28049 Madrid, Spain.
Antonio GarridoDepartment of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid, Cantoblanco, E-28049 Madrid, Spain.ORCID 0000-0003-3026-3330
Ana C CarreraDepartment of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid, Cantoblanco, E-28049 Madrid, Spain.ORCID 0000-0002-3999-5434
Consejo Superior de Investigaciones Científicas · ES

Funding

Asociación Española Contra el Cáncer 16035CARRComunidad de Madrid S2017/BMD-3804Spanish Ministry of Science, Innovation and Universities PID2019-106937RB-I00Spanish Ministry of Science, Innovation and Universities SAF2016-79195-R
6 · The paper itself

Abstract

Phosphatidylinositol-3,4,5-triphosphate (PIP

Indexed as

phosphorylationpost-translational modificationPTENsumoylationubiquitination

Identifiers

PMID36428706
PMCPMC9688753
OpenAlexW4309311509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.